Management of Anal Fissure
Start all patients with acute anal fissures on conservative therapy consisting of fiber supplementation, adequate fluid intake, sitz baths, and topical analgesics, as approximately 50% will heal with this approach alone. 1
Initial Assessment and Diagnosis
Suspect anal fissure based on the classic presentation of severe anal pain during and after defecation with bright red, scanty bleeding. Confirm diagnosis by visual inspection using gentle buttock traction to efface the anal canal—avoid instrumentation if the patient has severe pain, as this is traumatic and rarely yields additional diagnostic information 1.
Critical Red Flags
If the fissure is located off the midline (not posterior or anterior), immediately evaluate for underlying disease including Crohn's disease, HIV/AIDS, ulcerative colitis, tuberculosis, syphilis, leukemia, or malignancy 1. Midline location is the norm; lateral fissures are pathologic until proven otherwise.
Signs of chronicity include sentinel skin tag, hypertrophied anal papilla, fibrosis, and visible internal sphincter muscle at the fissure base 1.
Treatment Algorithm
Step 1: Conservative Management (First-Line for All Patients)
- Fiber supplementation
- Adequate fluid intake
- Sitz baths
- Topical analgesics
Acute fissures (symptoms <6 weeks, no sentinel pile) heal more readily than chronic fissures (>6 weeks or with fibrotic edges/sentinel pile) 1. Continue conservative therapy for an appropriate trial period, particularly in acute cases.
Step 2: Pharmacological Sphincter Relaxation (If Conservative Fails)
When conservative measures fail or symptoms are intolerable, escalate to medical sphincter relaxation. The goal is reversible reduction of resting anal pressure to promote healing without permanent sphincter damage 1.
Topical Therapy Options:
Topical calcium channel blockers (diltiazem or nifedipine) are preferred over nitroglycerin because they provide similar healing rates (25-50%) with fewer side effects and better patient compliance 1, 2. Recent evidence from Belgian and Italian guidelines supports 0.3% nifedipine plus 1.5% lidocaine as first-line topical therapy 3, 4.
- Nitroglycerin (GTN): Initial studies showed 70-80% healing rates, but more recent data demonstrates only 25-50% success. Headaches are common but rarely require discontinuation 1.
Botulinum Toxin Injection:
Botulinum toxin injection achieves 75-95% cure rates with low morbidity 1. The optimal injection site (internal vs. external sphincter) remains controversial, and long-term relapse rates require further study 1.
Continue topical therapy or botulinum toxin for 6-8 weeks before considering surgical options 3, 4.
Step 3: Surgical Intervention (For Refractory Cases)
Lateral internal sphincterotomy (LIS) is the definitive surgical treatment for chronic anal fissures that fail conservative and medical management, offering >90% cure rates with low relapse 1, 5, 6.
Indications for Surgery:
- Failure of 6-8 weeks of topical therapy
- Intolerable pain requiring immediate intervention
- Patient preference after informed discussion of risks
Surgical Options:
LIS remains the gold standard with technical simplicity, minimal morbidity, rapid symptom relief, high cure rates (>90%), and low relapse rates 1, 5, 6.
Fissurectomy (with or without flap) achieves approximately 80% success rates and is preferred in some European centers due to lower incontinence risk 6, 4.
Critical Caveat: Incontinence Risk
The major drawback of LIS is the risk of minor but sometimes permanent fecal incontinence in a minority of patients 1. This risk must be weighed against the high cure rate and rapid symptom relief. Avoid LIS in patients with pre-existing compromised sphincter function 1.
Special Considerations
Topical therapy and botulinum toxin can be used as first-line treatment (not merely salvage therapy) due to their low morbidity profiles, combining the safety of conservative treatment with more rapid effect 1. However, long-term failure rates may be significant 1.
Recent global audit data shows that 78% of patients receive conservative treatment initially, with 73% achieving resolution, while 22% undergo surgery with 88% resolution rates 7. This real-world data supports the stepwise approach outlined above.
Emerging Therapies
Newer treatments including platelet-rich plasma (PRP), adipose-derived regenerative cells (ADRCs), and percutaneous tibial nerve stimulation (PTNS) show promise but require further validation before routine clinical use 2.